8-K: Teva Pharmaceutical Reports Strong Q2 Growth, Raises Full-Year Guidance

Teva Pharmaceutical Industries Ltd. announced a 7% revenue increase in Q2 2024, driven by generics and AUSTEDO, leading to raised financial guidance for the year.

Summary

• Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency compared to Q2 2023.
• The generics business saw significant growth across all regions, with a 16% increase in the U.S., 8% in Europe, and 22% in International Markets in local currency terms.
• AUSTEDO revenue in the U.S. was $407 million, a 32% increase compared to Q2 2023, leading to a raised 2024 revenue outlook of approximately $1.6 billion.
• AJOVY global revenues reached $115 million, a 12% increase in local currency terms.
• The company accelerated the development timeline for duvakitug (Anti-TL1A), with top-line results expected in Q4 2024.
• Positive Phase 3 efficacy results were announced for olanzapine LAI (TEV' 749), with approximately 95% of target injections completed and no PDSS observed.
• SIMLANDI (adalimumab-ryvk) was launched in May 2024 as an interchangeable biosimilar to Humira.
• SELARSDI (ustekinumab-aekn) is preparing for a February 2025 launch as a biosimilar to Stelara.
• Teva's full-year 2024 business outlook is raised to revenues of $16.0 $16.4 billion, AUSTEDO revenues of ~$1.6 billion, adjusted EBITDA of $4.6 $5.0 billion, and non-GAAP diluted EPS of $2.30 $2.50.
• GAAP loss per share was $0.75, while non-GAAP diluted EPS was $0.61.
• Cash flow from operating activities was $103 million, and free cash flow was $324 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, particularly in generics and AUSTEDO, and raised financial guidance. While there are some negative aspects like the GAAP loss and decreased cash flow, the overall tone is optimistic and indicates a positive trajectory for the company.

Positives

• Teva experienced strong revenue growth in Q2 2024, driven by both generics and innovative products.
• The generics business showed robust growth across all regions, indicating a strong market presence.
• AUSTEDO's performance was exceptional, with a 32% increase in U.S. revenue and a raised full-year outlook.
• The company is making significant progress in its late-stage innovative pipeline, with accelerated development timelines for duvakitug.
• The launch of SIMLANDI as an interchangeable biosimilar is a positive step for the company.
• Teva has raised its full-year 2024 financial guidance, reflecting confidence in its future performance.
• The company's gross profit margin increased to 48.6% in Q2 2024, compared to 46.3% in Q2 2023.
• Non-GAAP operating income increased to $1,056 million in Q2 2024, compared to $1,011 million in Q2 2023.

Negatives

• Teva reported a GAAP net loss of $846 million and a loss per share of $0.75 for Q2 2024.
• Exchange rate movements negatively impacted overall revenues by $122 million.
• Cash flow from operating activities decreased to $103 million in Q2 2024, compared to $324 million in Q2 2023.
• The company recognized a tax expense of $630 million in Q2 2024, on a pre-tax loss of $246 million.
• AJOVY revenues in the United States segment decreased by 20% due to increased sales allowances.
• BENDEKA and TREANDA combined revenues decreased by 39% due to generic competition.
• Profit from the International Markets segment decreased by 45% due to lower other income and higher S&M expenses.

Risks

• Teva faces risks related to competition in the generics market, which could impact revenue and profitability.
• The company is subject to currency fluctuations, which can negatively impact financial results.
• Legal and regulatory challenges, including ongoing litigation, could result in significant costs and liabilities.
• The company's substantial debt could limit its ability to make new investments or engage in additional transactions.
• The company's tax rate is expected to be higher in 2024 compared to 2023, which could impact profitability.
• The company's API business divestiture may not be completed on time or at all.
• The company faces risks related to the ongoing conflict in Israel, which could disrupt operations.

Future Outlook

Teva has raised its full-year 2024 business outlook, projecting revenues of $16.0 $16.4 billion, AUSTEDO revenues of ~$1.6 billion, adjusted EBITDA of $4.6 $5.0 billion, and non-GAAP diluted EPS of $2.30 $2.50. The company expects its annual non-GAAP tax rate for 2024 to be between 14%-17%.

Management Comments

• Mr. Richard Francis, Teva's President and CEO, said, 'In the second quarter of 2024, we are encouraged by the positive momentum across each of the four pillars of our Pivot to Growth strategy.'
• Mr. Francis continued, 'We are also showing significant progress in on our late-stage innovative pipeline, underscored by the acceleration of the development timeline of duvakitug (Anti-TL1A), with top-line results now expected in the fourth quarter of 2024, and full data expected next year.'
• Mr. Francis stated, 'With these robust results, we are raising our financial guidance for 2024.'

Industry Context

Teva's strong performance in generics and the growth of AUSTEDO align with the broader trend of increased demand for generic and biosimilar medications. The company's focus on innovation and pipeline development is also consistent with the industry's push for new therapies. The launch of biosimilars like SIMLANDI and SELARSDI reflects the growing importance of these products in the pharmaceutical market.

Comparison to Industry Standards

• Teva's 7% revenue growth in Q2 2024 is a positive sign, especially when compared to some of its competitors in the generic pharmaceutical space, such as Viatris, which has faced revenue declines in recent quarters.
• The 32% growth in AUSTEDO revenue is particularly noteworthy, as it demonstrates Teva's ability to successfully commercialize innovative products, a key differentiator from companies solely focused on generics.
• The launch of SIMLANDI as an interchangeable biosimilar to Humira positions Teva to compete with other biosimilar manufacturers like Amgen and Sandoz, who have also launched adalimumab biosimilars.
• Teva's adjusted EBITDA margin of 25.3% in Q2 2024 is comparable to other large pharmaceutical companies, but there is room for improvement to reach the higher margins of some innovative drug developers.
• The company's free cash flow of $324 million in Q2 2024 is lower than some of its peers, indicating a need to improve cash generation.

Legal Proceedings

• The company reached a settlement agreement with the Israeli Tax Authorities (ITA), which resulted in an increase of $506 million in Teva's total income taxes in the second quarter of 2024.

Stakeholder Impact

• Shareholders will likely react positively to the raised financial guidance and strong revenue growth.
• Employees may benefit from the company's improved financial performance and growth prospects.
• Customers will have access to a broader range of generic and innovative medications.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial position favorably.

Next Steps

• Teva will continue to focus on its Pivot to Growth strategy, including expanding its innovative and biosimilar pipeline.
• The company will proceed with the development of duvakitug (Anti-TL1A), with top-line results expected in Q4 2024.
• Teva is preparing for the February 2025 launch of SELARSDI (ustekinumab-aekn).
• The company intends to divest its API business by the first half of 2025.
• Teva will continue to monitor and manage its debt and financial obligations.

Key Dates

Keywords

Teva, Pharmaceutical, Generics, AUSTEDO, AJOVY, Biosimilar, Revenue, EBITDA, Financial Results, Guidance, SIMLANDI, SELARSDI, duvakitug, Olanzapine LAI